ROCKVILLE, MD, USA I March 19, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase ...

RGX-202, a DMD gene therapy, has been well tolerated in an ongoing clinical trial and improved motor function for DMD boys, ...

This advertisement has not loaded yet, but your article continues below. SUMMERSIDE, P.E.I. — Mixed doubles curling is providing an opportunity for two household names in Canada to continue their ...